OCGN - Ocugen to Present at BIO International Convention 2024 | Benzinga
MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.
During the conference, Ocugen's leadership team will host meetings with potential partners and pharmaceutical executives to explore opportunities for the Company's dynamic pipeline addressing unmet medical needs—particularly its first-in-class ophthalmic modifier gene therapy and regenerative cell therapy platforms.
"We are excited to return to BIO this year and showcase the significant advancements we've achieved both clinically and strategically," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "BIO is an important opportunity to pursue collaborations that will propel the development of our first-in-class therapies while also enhancing shareholder value. We eagerly anticipate engaging with the distinguished industry professionals in attendance."
Ocugen's modifier gene therapy platform recently achieved several critical milestones, including the initiation of the OCU400 Phase 3 liMeLiGhT clinical trial for retinitis pigmentosa that affects approximately 300,000 people in the U.S. and Europe combined. Additionally, dosing was completed in Cohort 2 in both the OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy secondary to dry age-related macular degeneration (2-3 million people in the U.S. and Europe combined) and OCU410ST Phase 1/2 GARDian trial for Stargardt disease (approximately 100,000 people in the U.S. ...